Sumitomo Pharma

Sumitomo Pharma Company Limited
Company type	Public
Traded as	TYO: 4506
Industry	Biotech; Pharmaceuticals;
Predecessors	Dainippon Pharmaceuticals; Sumitomo Pharmaceuticals;
Founded	October 1, 2005 (merger of Dainippon Pharmaceuticals & Sumitomo Pharmaceuticals)
Headquarters	Doshomachi, Chuo-ku, Osaka, Japan
Key people	Hiroshi Nomura, (president and CEO)
Brands	Latuda; Lunesta; Aptiom; Orgovyx; Gemtesa; Brovana;
Revenue	$4.18 billion (¥555.54 billion) (FY 2022)
Operating income	-$580 million (-¥77.0 billion) (FY 2022)
Net income	-$728 million (-¥96.7 billion) (FY 2022)
Total assets	$8.55 billion (¥1,134.7 billion) (FY 2022)
Total equity	$3.06 billion (¥406.8 billion) (FY 2022)
Number of employees	6,250 (consolidated); 3,026 (non-consolidated) (as of March 31, 2023)
Website	www.sumitomo-pharma.com
	Footnotes / references; 1 2 3 4 5 "Financial Results for Fiscal 2022" (PDF). Sumitomo Pharmaceutical Company Limited. May 6, 2024. Retrieved May 6, 2024.;

Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.

[Financial_Results-1] 1 2 3 4 5 "Financial Results for Fiscal 2022" (PDF). Sumitomo Pharmaceutical Company Limited. May 6, 2024. Retrieved May 6, 2024.